Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 73

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 73
---
 was $30,000 for the three months ended June 30, 2025 compared to a loss of $5,000 for the same period last year.

For the three months ended June 30, 2025, our net loss was $1.7 million, or $0.25 per common share, compared to a net loss of $1.7 million, or $0.52 per common share for the three months ended June 30, 2024.

21

Comparison of the Nine Months Ended June 30, 2025 and 2024

Total operating expenses decreased by $0.6 million to $5.4 million for the nine months ended June 30, 2025 compared to $6.0 million for the nine months ended June 30, 2024.

			●

			The following table summarizes our R&D expenses incurred during the nine months ended June 30, 2025 and 2024, together with the dollar increase or decrease in those items:

			Nine Months Ended June 30, 2025 

			Change 

			June 30, 2025

			June 30, 2024

			$ 

			Program-specific external costs:

			EB06

			$
			292,200

			$
			-

			$
			292,200

			EB05

			1,269,963

			1,769,712

			(499,749
			)

			Other development and discovery programs

			101,227

			193,696

			(92,469
			)

			Total program-specific costs

			1,663,390

			1,963,408

			(300,018
			)

			Unallocated internal costs

			Non-program specific external costs

			1,199

			9,663

			(8,464
			)

			Unallocated internal costs

			778,602

			805,029

			(26,427
			)

			Total unallocated internal costs

			779,801

			814,692

			(34,891
			) 

			Total research and development costs

			2,443,191

			2,778,100

			(334,909
			)